山东大学学报 (医学版) ›› 2022, Vol. 60 ›› Issue (1): 118-120.doi: 10.6040/j.issn.1671-7554.0.2021.1080
陈峰1,高沛1,朱可嘉2,丁森泰1,2
中图分类号:
| [1] Stenehjem D, Tran D, Nkrumah M, et al. PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer[J]. Onco Targets Ther,2018, 2018(11):5973-5989. [2] Zavalishina LE, Andreeva YY, Olyushina EM, et al. Immunohistochemical study of the MSI phenotype of urothelial bladder cancer[J]. Arkh Patol, 2020, 82(1):5-14. [3] Fraune C, Simon R, Hube-Magg C, et al. MMR deficiency in urothelial carcinoma of the bladder presents with temporal and spatial homogeneity throughout the tumor mass[J]. Urol Oncol, 2020, 38(5): 488-495. [4] Eckstein M, Hartmann A, Strissel P, et al. Comparative analysis of tumour mutational burden(TMB)prediction methods and its association with determinants of the tumour immune microenvironment of urothelial bladder cancer(UBC)[J]. Ann Oncol, 2019, 30(5): 376-377. [5] Tang X, Qian WL, Yan WF, et al. Radiomic assessment as a method for predicting tumor mutation burden(TMB)of bladder cancer patients: a feasibility study [J]. BMC Cancer, 2021, 21(1): 823-823. [6] Albandar HJ, Fuqua J, Albandar JM, et al. Immune-related adverse events(irAE)in cancer immune checkpoint inhibitors(ICI)and survival outcomes correlation: to rechallenge or not? [J]. Cancers,2021, 13(5): 989-991. [7] Kenichi C, Toshiaki U, Keisuke A, et al. PD1-1-5 Frequency of immune-related adverse events of immune-checkpoint inhibitors for non-small cell lung cancer in our single institution[J]. Ann Oncol, 2021, 32(4):325-325. [8] Rubino R, Marini A, Roviello G, et al. Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy[J]. Endocr, 2021,74(1):172-179. [9] Lui DTW, Lee CH, Tang V, et al. Thyroid immune-related adverse events in cancer patients treated with anti-PD1/Anti-CTLA4 immune-checkpoint inhibitor combination: clinical course and outcomes[J]. Endocr Pract, 2021, 27(9): 886-893. [10] Kosuke N, Yosuke Y, Kenji K, et al. Primary lymphoepithelioma-like carcinoma of the esophagus with metastatic lymph node and gastric cancer[J]. Clin J Gastroenterol, 2021, 14(5): 1329-1336. [11] 李凯, 杨潇, 李鹏超, 等. 膀胱淋巴上皮瘤样癌1例报告[J].实用老年医学, 2021, 35(6): 636-637. [12] 范大铬, 黄海建, 吴春林. 膀胱淋巴上皮瘤样癌2例并文献复习[J].临床与实验病理学杂志, 2017, 33(10): 1153-1155. [13] Amin MB, Ro JY, Lee KM, et al. Lymphoepithelioma-like carcinoma of the urinary bladder[J]. Am J Surg Pathol, 1994, 18(5): 466-473. [14] Serrano GB, Funez FA, Lopez RG, et al. Bladder lymphoepithelioma-like carcinoma: bibliographic review and case report[J]. Arch Esp Urol, 2008, 61(6): 723-729. [15] Fang W, Hong S, Chen N, et al. PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival[J]. Oncotarget, 2015, 6(32): 33019-33032. [16] Alessandro R, Dalia RA, Giovanni B. PD-L1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer[J]. Cancers, 2021, 13(3): 558-558. [17] Rodrigues DN, Rescigno P, Liu D, et al. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer[J]. J Clin Invest, 2018, 128(10): 4441-4453. [18] 辇伟奇, 聂勇战, 应建明,等. 肿瘤突变负荷检测及临床应用中国专家共识(2020年版)[J].中国癌症防治杂志, 2020, 12(5): 485-494. [19] Zhou F, Huang Y, Cai WJ, et al. The genomic and immunologic profiles of pure pulmonary sarcomatoid carcinoma in Chinese patients[J]. Lung Cance, 2021, 15(3): 66-72. [20] Nalin L, Hong CS, Bindra RS. The role of mismatch repair in glioblastoma multiforme treatment response and resistance[J]. Neurosurg Clin N Am, 2021, 32(2): 171-180. [21] Machado-Neves R, Bernardo T, Elsa F, et al. Penile lymphoepithelioma-like carcinoma: a rare case with PD-L1 expression [J]. Int J Surg Pathol, 2021, 29(6): 690-692. |
| [1] | 李波波 李道堂 刘曙光 王兴武. 食管癌患者血清中DKK-1的表达[J]. 山东大学学报(医学版), 2209, 47(6): 58-61. |
| [2] | 徐平 于国放 李霞. 不同类型甲状腺上动脉PSV对Graves病与桥本氏甲状腺炎鉴别诊断的价值[J]. 山东大学学报(医学版), 2209, 47(6): 62-64. |
| [3] | 王欣，邢春燕，杨艳平. 血清磷酸丙酮酸水合酶检测对诊断侵袭性白念珠菌感染的临床价值[J]. 山东大学学报(医学版), 2209, 47(6): 92-94. |
| [4] | 杨宇凡,李悦,谢灏,林春华. 胆固醇水平与神经源性膀胱风险的因果关系[J]. 山东大学学报 (医学版), 2026, 64(5): 67-73. |
| [5] | 山东省医学会心电学分会山东省医学伦理学学会心电学分会. 心电图报告规范化书写专家共识(2026)[J]. 山东大学学报 (医学版), 2026, 64(4): 1-7. |
| [6] | 中国医师协会骨科医师分会智能骨科学组,中华预防医学会脊柱疾病预防与控制专业委员会脊柱脊髓损伤疾病预防与控制学组. 人工智能脊柱退变影像学测量位点与标注专家共识(2025)[J]. 山东大学学报 (医学版), 2026, 64(2): 1-10. |
| [7] | 罗淇,王霞,姜孟. 脑功能网络分析在失语症诊疗中的应用:病理机制分析、临床诊断与疗效评价[J]. 山东大学学报 (医学版), 2025, 63(8): 111-126. |
| [8] | 河南省生物医学工程学会立体心电图专业委员会,中国医药教育协会心电学专业委员会,山东中医药学会心电学专业委员会,青岛市医学会心电生理与起搏专科分会,全国医药技术市场协会远程心脏专业委员会. 心电向量图诊断标准规范化专家共识(2025)[J]. 山东大学学报 (医学版), 2025, 63(7): 1-10. |
| [9] | 刘保国,宋翔,赵晓文,毛亚丽. 血清STAT5B、NKAIN1 mRNA检测在乳腺癌中的应用价值[J]. 山东大学学报 (医学版), 2025, 63(7): 68-74. |
| [10] | 祝永才,谢艳,齐秋晨,李培龙,王传新,杜鲁涛. 基于外周血单个核细胞ATM基因甲基化的联合模型在胰腺癌早期诊断中的价值[J]. 山东大学学报 (医学版), 2025, 63(6): 78-88. |
| [11] | 赵汉卿,周新睿,李子建,唐兴. 循环肿瘤细胞联合血清学检测在非小细胞肺癌中的应用[J]. 山东大学学报 (医学版), 2025, 63(5): 79-85. |
| [12] | 魏旭鹏,常成,赵秀鹤. 模拟多系统萎缩的抗Homer3抗体相关自身免疫性小脑共济失调1例并文献复习[J]. 山东大学学报 (医学版), 2025, 63(5): 95-100. |
| [13] | 张艳艳,孙菁妮,朱凤英,杜以君,赵常梅,曹兴涛,张媛,吕明. 社会支持在脊髓损伤致神经源性膀胱患者自我管理与出院准备度间的中介作用[J]. 山东大学学报 (医学版), 2025, 63(3): 117-124. |
| [14] | 赵芸慕兰,高海燕. 中、高危分化型甲状腺癌患者术后 131I治疗反应及预后的影响因素[J]. 山东大学学报 (医学版), 2025, 63(2): 21-28. |
| [15] | 崔倩倩,李金鹏,吴豫丹,侯志平,孙玮螺,崔盼盼,何培元. 粪便miRNA对结直肠进展期腺瘤无创筛查的临床价值[J]. 山东大学学报 (医学版), 2025, 63(2): 43-50. |
|
||
